Armed an­ti­body play­er ADC lands a $105M mega-round to back pipeline con­struc­tion

Chris Mar­tin’s ADC Ther­a­peu­tics has roped in a $105 mil­lion mega-round to back his an­ti­body-drug con­ju­gate start­up ADC Ther­a­peu­tics, based in Lau­sanne, Switzer­land. Found­ing in­vestor Au­ven Ther­a­peu­tics came back in for the sec­ond fundrais­ing, along with the Wild Fam­i­ly Of­fice and phar­ma gi­ant As­traZeneca, which has been part­nered with the biotech.

The biotech has now raised $255 mil­lion for its work, with plans to launch an IPO when the tim­ing is right. And some of this new mon­ey is be­ing re­served to build out man­u­fac­tur­ing op­er­a­tions.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.